Reporting period July 2019 – September 2019

• Net sales amounted to DKK 0 (0).
• Operating profit was -7,030 m DKK (-1,296).
• Cash and bank assets amounted to 18,028 m DKK (544).
• Result per share was DKK -0.33 (-0.14).

Reporting period January 2019 – September 2019

• Net sales amounted to DKK 0 (0).
• Operating profit was -14,226 m DKK (-4,361).
• Cash and bank assets amounted to 18,028 m DKK (544).
• Result per share was DKK -0.63 (-0.46).
• Equity ratio was 91% (84).

Highlights during the period

• On July 12th, Scandion Oncology announced that the rights issue in the Company was oversubscribed by 200%. Scandion Oncology is provided approx. 29.3 million SEK before issue costs. In addition, if all warrants are fully exercised, Scandion Oncology will in Q3, 2020, obtain an additional 12.4 million SEK before issue costs.

Highlights after the period

• On October 1st, Scandion Oncology announced that Peter Høngaard Andersen has accepted the role as Chairman of the Board. Jørgen Bardenfleth will continue as Vice Chairman of the Board.

• On October 1st, Scandion Oncology announced that the Company has submitted an application to the Danish Medicines Agency for permission to conduct a clinical Phase II study in patients with metastatic colorectal cancer.

• On October 1st, Scandion Oncology announced that the report on the in vivo animal data on antibiotic resistance and SOM-001 is extended until mid-Q4 2019 due to shortage in slots at the provider.

• On October 14th, Scandion Oncology announced that the European Patent Office (“EPO”) has granted the company’s patent application for SCO-101 when combined with chemotherapy. Patent is valid until May 2037.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com 

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.